6.21

1.72% 0.15

Outlook Therapeutics Inc (OTLK)

Overview News Price History Financials Discussions Forecast Stock Split

Outlook Therapeutics Inc stock is traded at $6.21, with a volume of 71,542. It is up +1.72% in the last 24 hours and up +17.86% over the past month. Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Previous Close:

$6.06

Open:

$6.03

24h Volume:

71,542

Relative Volume:

0.30

Market Cap:

$143.35M

Revenue:

Net Income/Loss:

$-51.50M

P/E Ratio:

-24.84

EPS:

-0.25

Net Cash Flow:

$-47.10M

1W Performance:

+7.39%

1M Performance:

+17.86%

6M Performance:

-28.33%

1Y Performance:

-27.89%

1-Day Range:

$6.00

$6.32

1-Week Range:

$5.66

$6.32

52-Week Range:

$4.61

$12.85

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name

Outlook Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(609) 619-3990

Address

111 S. WOOD AVENUE, ISELIN, NJ

Employee

Twitter

Next Earnings Date

2024-08-14

Latest SEC Filings

OTLK's Discussions on Twitter

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-03-23	Initiated	Guggenheim	Buy
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight
Oct-31-22	Initiated	BTIG Research	Buy
Sep-13-22	Initiated	Chardan Capital Markets	Buy
Sep-11-19	Initiated	Ladenburg Thalmann	Buy
May-16-19	Initiated	Oppenheimer	Outperform
Apr-22-19	Initiated	Ascendiant Capital Markets	Buy

View All

Outlook Therapeutics Inc Stock (OTLK) Latest News

Nov 02, 2024

Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Simply Wall St

Nov 02, 2024

Oct 30, 2024

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Oct 30, 2024

Oct 28, 2024

(OTLK) Trading Signals - Stock Traders Daily

Oct 28, 2024

Oct 18, 2024

Outlook Therapeutics' (OTLK) Buy Rating Reiterated at BTIG Research - MarketBeat

Oct 18, 2024

Outlook Therapeutics Participates in a Virtual Investor CEO Connect Segment - Marketscreener.com

Oct 18, 2024

How the (OTLK) price action is used to our Advantage - Stock Traders Daily

Oct 18, 2024

Oct 17, 2024

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment - GlobeNewswire

Oct 17, 2024

Oct 16, 2024

Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 16, 2024

Oct 14, 2024

Severe Acute Respiratory Syndrome (SARS) Therapeutics Market 2023 Outlook By Product, Trends and Forecast To (2024-2034) – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024

Oct 11, 2024

OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - ForexTV.com

Oct 11, 2024

ROSEN, A LEADING LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important - EIN News

Oct 11, 2024

OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Oct 11, 2024

Oct 10, 2024

Outlook Therapeutics Awaits Wet AMD Trial Results Of ONS-5010 - RTTNews

Oct 10, 2024

Oct 05, 2024

OTLK DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionOTLK - AsiaOne

Oct 05, 2024

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Oct 05, 2024

(OTLK) On The My Stocks Page - Stock Traders Daily

Oct 05, 2024

Oct 01, 2024

Outlook Therapeutics CFO buys $28.4k in company stock - Investing.com India

Oct 01, 2024

Insider Buying: CFO Lawrence Kenyon Acquires Shares of Outlook T - GuruFocus.com

Oct 01, 2024

Sep 30, 2024

Outlook Therapeutics CFO buys $28.4k in company stock By Investing.com - Investing.com Australia

Sep 30, 2024

Neumora Therapeutics' SWOT analysis: navacaprant's potential lifts stock outlook - Investing.com

Sep 30, 2024

Sep 24, 2024

Great Point Partners LLC Raises Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Sep 24, 2024

(OTLK) Investment Analysis - Stock Traders Daily

Sep 24, 2024

Great Point Partners LLC Grows Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat

Sep 24, 2024

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by First Light Asset Management LLC - Defense World

Sep 24, 2024

Sep 23, 2024

Checking in on Outlook Therapeutics Inc (OTLK) after recent insiders movement - Knox Daily

Sep 23, 2024

Investor’s Toolkit: Key Ratios for Assessing Outlook Therapeutics Inc (OTLK)’s Performance - The Dwinnex

Sep 23, 2024

A year in review: Outlook Therapeutics Inc (OTLK)’s performance in the last year - US Post News

Sep 23, 2024

Sep 16, 2024

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series - ForexTV.com

Sep 16, 2024

Sep 13, 2024

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series - GlobeNewswire

Sep 13, 2024

Sep 12, 2024

OTLKOutlook Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Sep 12, 2024

Sep 11, 2024